The treatment of hypertension has a significant impact on health care costs.
Introduction
The treatment of hypertension has a significant impact on health care costs. 1 The issues are complex and involve decisions about indications for treatment as well as of choice of treatment. However, not only cost of drug intervention should be included in the assessment. Potential savings from reductions in coronary and vascular events should also be taken into account. In a full economic evaluation, costs must be related to benefits in terms of improvements in survival and quality of life.
Numerous health economic studies related to antihypertensive therapy have been published over the last 20 years. 2 Earlier studies were based on intermediate clinical end points, for example reduction in diastolic blood pressure, and epidemiological models of changes in morbidity and mortality due to an intervention. 3 Studies based on actual risk reduction, 4 shown in controlled clinical trials, are in most cases based on comparisons between placebo and active therapy. Thus, the focus has been to maximise internal validity, rather than the external validity of the studies. 
Background and rationale
ASCOT gives an opportunity to improve the knowledge of the economic aspects of different strategies for the treatment of hypertension. So far, no costeffectiveness study has compared newer antihypertensive drug classes, eg, calcium antagonists and angiotensin-converting enzyme (ACE)-inhibitors, with traditional agents, eg, beta-blockers and diuretics, using data from a comparative clinical trial. Available estimates have been undertaken using different assumptions about the impact on coronary heart disease (CHD) events. 5 By using the primary and secondary endpoints in the analysis, the precision in the health economic estimates will increase in comparison with earlier estimates. The open naturalistic design of this study and the option to change therapy according to treatment target and patient acceptance of therapy will increase the external validity of the results. Given a proposed average follow-up of all patients of 5-years, irrespective of changes in drug therapy, the calculations of costs and health outcomes may be undertaken without the need to impute data for missing observations.
Objectives
The objective of the health economic study is to answer the following two questions:
(1) Is it cost-effective to treat hypertensive patients, who have at least three additional risk factors, with calcium channel blockers and ACE-inhibitors as needed, in comparison with beta-blockers and diuretics as needed? (2) Is it cost-effective to add lipid-lowering therapy to antihypertensive treatment in patients with a total serum cholesterol level р6.5 mmol/l?
Study methods
The primary health economic analysis will be an estimation of cost per event avoided. To be able to make wider comparisons with other studies within the area, cost per life-year gained and, as a sensitivity analysis, cost per quality-adjusted life years will be calculated in a separate secondary health economic analysis. Events are defined as in the primary end point of the trial, ie, non-fatal myocardial infarction plus fatal CHD. As a sensitivity analysis, total cardiovascular events and procedures will also be included in the event definition. In the secondary health economic analysis, life-year-gained will be calculated based on difference in total mortality between the two antihypertensive treatment groups and the lipid-lowering vs placebo groups, respectively. Two analytical approaches will be used:
(1) A within-trial analysis, ie, the analysis will be based only on the average 5-year follow-up (primary analysis). (2) A modelling approach, ie, the analysis will be extrapolated to the patients' expected life-time (secondary analysis).
The within-trial analysis
The within-trial analysis will be done in parallel with the clinical analysis. This approach will only estimate the direct health services cost per event avoided. Costs will be based on utilisation of medication and hospitalisation over the average 5-year follow-up period. Data on variation in out-patient visits between groups will be difficult to include in the analysis, since they depend on the trial situation (protocol driven costs). Such differences in costs can be calculated, for example based on observational study data, and be included in a sensitivity analysis.
If there is a difference in total mortality between the two antihypertensive treatment groups and the lipid-lowering vs placebo groups, respectively, within the average 5-year follow-up period, a cost per life-year gained will be calculated. Life-year gained will then be based on the within-trial gain in life expectancy, using Kaplan-Meyer and published data on expected survival. 6 A special analysis will be undertaken for the subgroup of patients with diabetes mellitus.
The modelling approach
In the modelling approach, the time period will be the patients' remaining expected lifetime. Two different cost concepts will be utilised based on study perspective:
(1) Direct health care costs only (health care perspective). (2) Direct health care costs + indirect costs + cost per added life years (societal perspective).
In this secondary analysis, the results will be presented as cost per life-year gained and, as a sensitivity analysis, cost per quality adjusted life-year (QALY) gained. Utility weights will be based on local published weights, for example weights collected through the EuroQol 5D. If possible, a substudy will be performed in Sweden with the objective to collect utility weights before and after a cardiovascular event.
It is important to calculate cost-effectiveness with different definitions of cost as well as outcome. Different decision makers have different perspectives, and there is also a need to compare the result to previous studies using different cost concepts and different outcomes. 7 The estimations will be based on the premises that the study drug will only be used for an average of 5 years and that there are no direct clinical drug effects beyond the average 5-year study period. The cost-effectiveness estimate will thus be for the avoidance of the first event. For secondary prevention, earlier studies have already provided evidence on cost-effectiveness. Data on cardiovascular events from the clinical trial will be used for the simulation. 8 CHD risk equations needed in the various models will be defined, for example including age, sex, blood pressure, cholesterol level (total, LDL, HDL), diabetes mellitus, and smoking. The exact specification of the equations will be included in the final protocol and will be available prior to the unblinding of data.
In the modelling approach, separate analyses will be performed for the age groups 40-49 and 50-65 years of age with indirect costs, ie, costs due to loss of production. Information on loss of productive capacity after a cardiovascular event may be based on a sub-study among the Swedish patient population briefly outlined above.
Data
The health economic data of particular relevance, in addition to the cardiovascular end points, includes actual drug utilisation, number of hospitalisations and number of hospital days. These items will be used for the calculations of cost variations between the various study arms. The first alternative for costing hospitalisation will be to use costs according to the diagnoses related group (DRG) costing principle. DRGs will be established, based on data from the case record form. A separate process to make DRGclassification of the events will be established. A list of relevant DRGs will be added to the final health economic protocol. The second alternative for costing hospitalisation is simply to use the average per diem cost per hospital day.
A health economic database will be established that is consistent with the database for the primary clinical analysis, including a model how to handle censored data. The data used for the economic evaluation will have the same quality control measures as all other data collected in the trial. A special effort will be made to make sure that the health economic data in the UK and Scandinavian arm respectively are consistent.
Costing will be performed by multiplication of the resource units collected in the trial with unit costs collected outside the trial for different countries. Unit costs will be collected late in the study in order to have them as up-to-date as possible at the time of publication.
Analysis
In the within-trial analysis the stochastic information will be utilised. Confidence interval for the incremental cost-effectiveness ratio (ICER), netbenefits and acceptability curves will be estimated. For the net-benefit calculation an algorithm for finding a starting value of an avoided event will be established. In addition, a multiple regression analysis will be performed to analyse the most important variables that explain the variation in costs.
In the modelling approach, both costs per life-year gained and costs per quality-adjusted life years will be calculated. The uncertainty in these analyses will be investigated by using various forms of sensitivity analyses (one-way, two-way, etc). A full analytical plan will be developed and presented in the final protocol, prior to unblinding of the study.
Various methods are available for calculating costs in an international study where heterogeneity of health economic data exist. The approach suggested is the following:
Test if there are important differences between quantities in Scandinavia and the UK:
(i) If no difference; calculate the total direct costs using Swedish unit costs and whole study quantities + one calculation using UK unit costs. (ii) If different; calculate the Swedish prices and Scandinavian quantities plus UK prices and UK quantities. This latter calculation will lose some of the power in the within-trial analysis. The most appropriate way to pool the results from the Scandinavian results with the UK results is an issue that remains to be resolved.
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Discussion
ASCOT is designed to compare the efficacy of different strategies for the treatment of hypertension and hyperlipidaemia. The purpose of the economic evaluation is to investigate the cost-effectiveness of the different strategies. There are several advantages to base an economic evaluation on a single clinical trial. The alternatives are clearly specified and the relation between input and outcome is carefully controlled in order to avoid bias. Statistical analysis can be performed on the precision of different estimates of both costs and outcome. However, the road from efficacy to cost-effectiveness is not a straight and easy one. While the clinical trial aims at maximising the internal validity of the results, the economic evaluation must be undertaken with an eye on the external validity of the analysis. Decision-makers in different countries will be interested in the cost-effectiveness applying the prices and unit costs that are relevant to their country. These data must be collected outside the trial, and the difficult problem of the aggregation of health care resources over countries must be addressed. The variability in the use of health care resources between countries can be considerable due to differences in treatment patterns, determined by availability of resources, relative prices and traditions. In addition, the strict protocol in the clinical trial affects resource utilisation as well as outcome.
But cost is not the only problem. The end points in a clinical trial are having several limitations for use in an economic evaluation. There are problems with comparability, which limits the external validity. We cannot compare the cost per myocardial infarction avoided in one study with the cost per hip fracture avoided in another study. Even the comparison of cost per additional survivor or cost per life-year gained within the trial can be misleading. They are, for example, dependent on the length of the trial. The solution to this problem is to calculate the cost per (quality-adjusted) life-year gained. This requires modelling, since the gain in life expectancy is dependent on survival at the end of the trial.
The proposed methodology for economic evaluation in ASCOT reflects this balance between making optimal use of the internal validity from the clinical trial at the same time making the economic evaluation relevant for different clinical and administrative decision-makers in different countries.
